Connect Biopharma Holdings Limited
CNTB
Rank in Stocks
#22971
Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical... Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company dedicated to discovering and advancing immune modulators. Its primary objective is to develop treatments for serious autoimmune diseases and various inflammatory conditions. The company's lead investigational therapy is CBP-201, an anti-interleukin-4 receptor alpha antibody. This candidate is currently in Phase IIb clinical trials, targeting inflammatory allergic diseases such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Additionally, Connect Biopharma's pipeline includes CBP-307, a small molecule designed to modulate sphingosine 1-phosphate receptor 1. This receptor plays a crucial role in regulating T cell movement from lymph nodes into the bloodstream. CBP-307 is in Phase II development for treating autoimmune-related inflammatory disorders. Another preclinical-stage asset, CBP-174, is an orally administered small molecule histamine receptor 3 antagonist, being investigated for chronic pruritus (itch) associated with skin inflammation. The portfolio also features CBP-233, a humanized antibody in preclinical development that targets interleukin-33, a cytokine recognized for its involvement in T helper 2 inflammation. Established in 2012, the company maintains its headquarters in Taicang, China.
Share Price
$0.7503
Last synced: 2026-11-09
Market Cap
$47.25M
Change (1 day)
2.96%
Change (1 year)
-53.40%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Connect Biopharma Holdings Limited (CNTB)
Category
Healthcare
Operating Margin for Connect Biopharma Holdings Limited (CNTB)
Operating Margin as of November 2026 TTM: -1,795.61%
According to Connect Biopharma Holdings Limited's latest financial reports, its current operating margin (TTM) is -1,795.61%. At the end of 2025 the company had an operating margin of -90,740.63%.
Operating Margin history for Connect Biopharma Holdings Limited from 2018 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -1,795.61% | -98.02% |
| 2025 | -90,740.63% | 105,118.73% |
| 2024 | -86.24% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.02% |
US
|
|
| -149.01% | -99.92% |
US
|
|
| 25.57% | -100.01% |
AU
|
|
| 31.23% | -100.02% |
BE
|
|
| 29.35% | -100.02% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Connect Biopharma Holdings Limited's operating margin
What is Connect Biopharma Holdings Limited's operating margin?
Connect Biopharma Holdings Limited's operating margin is -1,795.61%, as of Nov 2026.
What was Connect Biopharma Holdings Limited's operating margin in 2025?
In 2025, Connect Biopharma Holdings Limited's operating margin was -90,740.63%, compared with -86.24% in 2024.
How has Connect Biopharma Holdings Limited's operating margin changed since 2020?
From 2020 to 2025, Connect Biopharma Holdings Limited's operating margin was highest in 2023 (0.00%) and lowest in 2025 (-90,740.63%).
How does Connect Biopharma Holdings Limited's operating margin compare with similar companies?
Connect Biopharma Holdings Limited's operating margin (-1,795.61%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.